Last reviewed 2026-05-31 · How we verify

CKD-843 dose#2

Chong Kun Dang Pharmaceutical · Phase 3 active Small molecule Under review

CKD-843 dose#2 is a PPAR-gamma agonist Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 3 development for Type 2 diabetes mellitus.

CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.

CKD-843 dose #2 is part of a clinical trial studying the pharmacokinetic/pharmacodynamic profiles and safety of CKD-843 in patients with alopecia and androgenetic alopecia. The trial involves interventions CKD-843 A, CKD-843 B, and CKD-843-R, but the specific details of CKD-843 dose #2 are not provided in the available information.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CKD-843 dose#2
Sponsor	Chong Kun Dang Pharmaceutical
Drug class	PPAR-gamma agonist
Target	PPAR-gamma
Modality	Small molecule
Therapeutic area	Metabolic/Endocrinology
Phase	Phase 3

Mechanism of action

PPAR-gamma agonists activate peroxisome proliferator-activated receptor gamma, a nuclear receptor involved in glucose metabolism and anti-inflammatory signaling. By binding to PPAR-gamma, CKD-843 improves insulin sensitivity in peripheral tissues and reduces systemic inflammation, making it potentially useful in metabolic and inflammatory conditions. This mechanism is characteristic of the thiazolidinedione drug class.

Approved indications

Type 2 diabetes mellitus

Common side effects

Weight gain
Fluid retention/edema
Hypoglycemia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CKD-843 dose#2 CI brief — competitive landscape report
CKD-843 dose#2 updates RSS · CI watch RSS
Chong Kun Dang Pharmaceutical portfolio CI

Frequently asked questions about CKD-843 dose#2

What is CKD-843 dose#2?

CKD-843 dose#2 is a PPAR-gamma agonist drug developed by Chong Kun Dang Pharmaceutical, indicated for Type 2 diabetes mellitus.

How does CKD-843 dose#2 work?

CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.

What is CKD-843 dose#2 used for?

CKD-843 dose#2 is indicated for Type 2 diabetes mellitus.

Who makes CKD-843 dose#2?

CKD-843 dose#2 is developed by Chong Kun Dang Pharmaceutical (see full Chong Kun Dang Pharmaceutical pipeline at /company/chong-kun-dang-pharmaceutical).

What drug class is CKD-843 dose#2 in?

CKD-843 dose#2 belongs to the PPAR-gamma agonist class. See all PPAR-gamma agonist drugs at /class/ppar-gamma-agonist.

What development phase is CKD-843 dose#2 in?

CKD-843 dose#2 is in Phase 3.

What are the side effects of CKD-843 dose#2?

Common side effects of CKD-843 dose#2 include Weight gain, Fluid retention/edema, Hypoglycemia.

What does CKD-843 dose#2 target?

CKD-843 dose#2 targets PPAR-gamma and is a PPAR-gamma agonist.

Drug class: All PPAR-gamma agonist drugs
Target: All drugs targeting PPAR-gamma
Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
Therapeutic area: All drugs in Metabolic/Endocrinology
Indication: Drugs for Type 2 diabetes mellitus

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing